<DOC>
	<DOCNO>NCT01147341</DOCNO>
	<brief_summary>Purpose study determine Cimzia safe effective subject receive previous treatment TNF-alpha inhibitor Cimzia .</brief_summary>
	<brief_title>Can TNF-Alpha Incomplete Secondary Responders Attain Safe Efficacious Response Switching Cimzia</brief_title>
	<detailed_description>This Phase IV , randomize , multi-center , double-blind , parallel-group 12-week study Cimzia concomitant methotrexate ( MTX ) DMARD compare MTX DMARD alone patient inadequate secondary therapeutic response TNF-alpha inhibitor define active rheumatoid arthritis ( RA ) follow 12-week open-label phase concomitant MTX DMARD Cimzia . Subjects must washout previous TNF inhibitor least 4 week prior baseline visit . Subjects unable tolerate MTX must stable dose another non-biologic DMARD least 3 month . Subjects ' diagnosis RA must base 1987 Revised American Rheumatism Association Criteria Classification Rheumatoid Arthritis . Subjects screen eligibility , 28 day later , baseline visit , randomize one two treatment group ( 2:1 ) : Cimzia placebo ( addition concomitant MTX DMARD ) . All subject continue MTX/other DMARD dose utilized prior study entry . After Week 12 study visit , subject opportunity continue study open-label Cimzia treatment ( use induction regimen subject , regardless treatment blind phase ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Have diagnosis RA least 6 month Have receive treatment TNFalpha inhibitor Be receive Methotrexate ( folic acid ) dose least 10mg/week another nonbiologic DMARD Methotrexate intolerant *Have least 6 tender joint 6 swollen joints* Have CRP great equal ULN Availability chest xray show evidence active TB infection Prior exposure Cimzia Prior treatment Bcell deplete therapy No significant response previous TNF inhibitor Congestive heart failure Clinically abnormal laboratory test History cancer Active TB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>anti-TNF therapy</keyword>
</DOC>